-
2014 China Drug Evaluation List
Time of Update: 2015-01-20
Guide: 2014 has been turned over In this year, the drug with the most popular topic is hepatitis C drug sofosbuvir, whose popularity runs through the first year to the end of the year; the policy with
-
The new Alzheimer's drug of Beijing New Pharmaceutical Co., Ltd. kabalatin bitartrate capsule is expected to be approved this year
Time of Update: 2015-01-20
According to the information on the website of the State Food and Drug Administration (CFDA), Beijing new pharmaceutical's cabalatine heavy tartrate capsule was applied for acceptance in June 2011, wh
-
Beijing furuikangzheng class 3.1 new drug: the first approved clinical application
Time of Update: 2015-01-20
The class 3.1 new drug konivartan hydrochloride declared by Beijing furuikangzheng medicine was approved for clinical application on January 14, 2015, and its current status is "under approval" This i
-
Gsk573719, a long-acting muscarinic antagonist of GlaxoSmithKline, was approved for clinical use in China
Time of Update: 2015-01-20
At present, the clinical application of GSK's long-acting muscarinic antagonist gsk573719 (umeclidinium) has left the task sequence of supplementary data, and was approved on January 14, 2015 Recently
-
CDE drug review weekly report (2015.1.11-1.17)
Time of Update: 2015-01-19
There are 23 chemicals, 6 traditional Chinese medicines, 4 biological products for treatment, 2 biological products for prevention and 9 in vitro diagnostic reagents among the 44 drugs under approval
-
Pharmaceutical research and development of "palmtop chemistry" app launched by Wuxi apptec can also "place an order for mobile phone"
Time of Update: 2015-01-19
Mobile Internet is sweeping all traditional industries in a trend that has never been seen before When Internet companies are pouring into the pharmaceutical industry, pharmaceutical companies are als
-
The clinical application of 1.1 class ad new drug piperidmethyl ketone in South China new drug and health hospital was accepted
Time of Update: 2015-01-15
Recently, Guangzhou biomedical and Health Research Institute and Health Research Institute of Chinese Academy of Sciences and Guangdong South China new drug development center class 1.1 chemical new d
-
2014 China drug review report
Time of Update: 2015-01-13
1 Chemical drugs 1 Application acceptance: the number of chemical drug applications has increased year by year, with the increase mainly concentrated in new drugs and import re registration In 2014, t
-
Dongcheng pharmaceutical's key product, natrium traxaparin calcium, has been approved and delayed in preparation for on-site inspection
Time of Update: 2015-01-12
Naltrexaparin calcium, also known as low molecular weight heparin calcium, was declared by Dongcheng pharmaceutical in May 2007 According to the company, the product is a key product developed by the
-
CDE drug review weekly report (2015.1.4-1.10)
Time of Update: 2015-01-12
Among the 100 drugs approved to enter the approval process this week, only 29 are chemical drugs, and the rest are traditional Chinese medicine Among the 29 chemicals, 8 are imported, 2 are of 1.1, 8
-
The production of three kinds of peptizine granules will be approved soon
Time of Update: 2015-01-11
Prior to that, Deng Xiang, Secretary of the board of directors of Hisilicon, predicted that the product is expected to be approved in 2014, and the sales revenue after IPO will reach 300 million yuan
-
Fuan pharmaceutical's class 3.1 new high blood pressure drug, Nabil hydrochloride, will enter the field for examination and impact the first imitation in China
Time of Update: 2015-01-11
According to the public information, Nabil hydrochloride is the third generation beta blocker developed by Johnson & Johnson, which is used to treat primary hypertension and mild to moderate stable ch
-
6 major scientific and technological projects of new drug creation won 2014 National Science and Technology Award
Time of Update: 2015-01-10
1、 The foundation of science and technology of traditional Chinese medicine in China is relatively weak, resulting in the fuzzy function of traditional Chinese medicine, extensive pharmaceutical techn
-
The new microchip biological 1.1 drug xidaban (epsiloxane) has been approved by CFDA for marketing
Time of Update: 2015-01-09
Cidabamide belongs to a new mechanism of action - epigenetic regulators of anti-tumor drugs CFDA approved it for the treatment of relapsed and refractory peripheral T-cell lymphoma Peripheral T-cell l
-
Hualing pharmaceutical raised US $25 million to develop new diabetes drug therapy
Time of Update: 2015-01-09
With the integration of China's pharmaceutical market and the international market, Chinese local pharmaceutical companies are gradually going out of the country, and are widely concerned by market pe
-
Shenwei pharmaceutical "scientific research project of traditional Chinese medicine injection" won the national science and Technology Progress Award
Time of Update: 2015-01-09
On the morning of January 9, the CPC Central Committee and the State Council held the 2014 National Science and technology award conference in the Great Hall of the people in Beijing Shenwei Pharmaceu
-
Seperation and synthesis of the compound "hiponol" with hypoglycemic activity from seaweed by Institute of Oceanography, Chinese Academy of Sciences
Time of Update: 2015-01-08
Recently, Shi Dayong, a researcher at the center for research and development of marine biotechnology, Institute of Oceanography, Chinese Academy of Sciences, has successfully obtained the US patent a
-
CDE drug review report in December 2014
Time of Update: 2015-01-08
Guide reading: Jiangsu Hengrui and dongyangguang have added 1.1 new varieties; antakalin, a new antihypertensive drug of Enhua pharmaceutical, has been applied for listing again; heplatide, a new Anti
-
The first monoclonal antibody "ambroxol" of Haizheng Pharmaceutical Co., Ltd. has completed on-site inspection
Time of Update: 2015-01-07
According to the information on January 7 on the website of the State Food and Drug Administration (CFDA), Haizheng pharmaceutical's heavyweight new drug "ambenol" (recombinant human tumor necrosis fa
-
Yuheng pharmaceutical, a new Chinese medicine, Ginkgolide B and ginkgolide B injection received supplementary information notice
Time of Update: 2015-01-07
Yuheng pharmaceutical announced on the evening of January 6 that the company had received the notice of supplementary information (ysbz [2015] No 0011, ysbz [2015] No 0012) issued by the drug review c
